I-Mab Bio and Jiangsu Nhwa Pharma Join China-US-Canada CNS Collaboration
publication date: Apr 8, 2019
Shanghai I-Mab Biopharma and Jiangsu Nhwa Pharma have joined with two western healthcare organizations to develop a novel nasal-delivered immuno-stimulatory therapy for neurological diseases. The collaboration includes the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital and Biodextris, a Montreal biologics CDMO. The Brigham team will be responsible for preclinical development including biomarkers and early clinical studies. I-Mab and Nhwa will provide financial, technical, regulatory, and business support for R&D and commercial development. More details....
Stock Symbol: (SHZ: 002262)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.